Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cybin Inc (NY: CYBN ) 0.3036 -0.0114 (-3.62%) Streaming Delayed Price Updated: 1:44 PM EDT, Jul 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Cybin Inc < Previous 1 2 3 4 5 6 7 8 9 ... 20 21 Next > Cybin Reports Access To $101M To Sustain Deuterated Psychedelics Programs, Q2 Numbers & 2024 Goals November 15, 2023 Clinical-stage psychedelics biotech Cybin Inc. (NYSE: CYBN) released its financial results for second quarter ended September 30, 2023. Via Benzinga Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More November 12, 2023 Veterans Day: Can Psychedelic Treatment Help Stem PTSD-Related Suicides Among Veterans? Via Benzinga Topics Initial Public Offering Exposures Securities Market Cybin Launches Five-Day Units Offering For Up To $64M, Suspends Prior LPC Funding Deal November 10, 2023 Clinical-stage psychedelics biotech Cybin Inc. (NYSE: CYBN) has announced a new underwritten offering of 66.66 million units to one of its largest institutional shareholders as well as new... Via Benzinga Psyched: DEA's Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More November 06, 2023 DEA Psilocybin Rescheduling Denial Overruled By Federal Appeals Court Via Benzinga Topics Economy Exposures Interest Rates Single Dose Of Cybin's Psilocybin Shows Compelling Patient Outcomes, Phase 2 Results Find November 01, 2023 Psychedelics company Cybin Inc. (NYSE: CYBN) shared its Phase 2 study interim results for its psilocybin analog CYB003 Via Benzinga Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More October 29, 2023 Cybin Officially Owns Small Pharma, Gets Three New International Patents Granted Via Benzinga Topics Intellectual Property Exposures Intellectual Property Cybin's Deuterated Psychedelics Programs Protected By Three New International Patents October 26, 2023 Cybin’s (NYSE: CYBN) deuterated psychedelics programs received two patent grants from the United States Patent and Trademark Office (USPTO,) and one from the European Patent Office (EP.) Via Benzinga Topics Intellectual Property Exposures Intellectual Property Cybin Officially Owns Small Pharma: Plans For New 'International Leader' In Psychedelic Therapeutics October 23, 2023 Psychedelics companies Cybin Inc. (NYSE: CYBN) and Small Pharma Inc. (OTCQB: DMTTF) have completed their August acquisition agreement. Via Benzinga Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted October 22, 2023 Jada Pinkett Smith Opens Up About Ayahuasca: It Helped Her Overcome Depression And Suicidal Thoughts Via Benzinga Small Pharma's Q2 2024 Financial Highlights Ahead Of Cybin Merger For Global DMT Business October 20, 2023 Small Pharma Inc. (OTCQB: DMTTF), the short-acting psychedelics biotech about to be purchased by Cybin Inc. Via Benzinga Moving Closer To Cybin Acquisition, Small Pharma Obtains Final Order Approving Arrangement October 18, 2023 Short-acting psychedelics biotech Small Pharma Inc. Via Benzinga Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More October 16, 2023 Cybin And Small Pharma Shareholders Green Light Acquisition Resolution Via Benzinga Exposures Product Safety Cybin And Small Pharma Shareholders Green Light Acquisition Resolution: Results & Expected Dates October 13, 2023 Clinical-stage psychedelics biotechs Canada-based Cybin Inc. (NYSE: CYBN) and UK-based Small Pharma Inc. Via Benzinga Psyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & More October 06, 2023 Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares Via Benzinga Cybin Completes Dosing In Phase 2 Study Of CYB003 For Major Depressive Disorder Treatment October 03, 2023 Cybin Inc. (NYSE: CYBN), a clinical-stage biotech company developing novel psychedelic-based mental health treatments, has completed dosing of the final participant cohort in the Via Benzinga Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares October 03, 2023 NY Mets owner billionaire Steve Cohen has bought as many as 119,092,680 ordinary shares of clinical-stage biopharmaceutical company Bionomics Limited (NASDAQ: BNOX) through his Point72 asset management... Via Benzinga Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More October 02, 2023 Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of... Via Benzinga Cybin And Fluence Partner To Support EMBARK Training For Phase 3 CYB003 Trial For Depression September 26, 2023 Clinical-stage psychedelics biotech Cybin Inc. Via Benzinga Depression Relief: Possible Therapy Boost With DMT & SSRIs, Per Small Pharma Clinical Results September 26, 2023 New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of psychedelics and traditional pharma for the treatment of major depressive disorder (MDD) are out. Via Benzinga Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More September 26, 2023 Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge Via Benzinga Topics Economy Exposures Interest Rates Cybin Delivers Highest Dose Of Psilocybin Analog In Phase 2 For Major Depression September 21, 2023 Clinical-stage psychedelics biotech Cybin (NYSE: CYBN) has completed enrollment in its Phase 2 study of novel deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive... Via Benzinga Why Fresh Tracks Therapeutics Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket September 20, 2023 Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares rose 70.2% to $0.8937 in pre-market trading after falling 10% on Tuesday. Via Benzinga Why Elutia Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket September 19, 2023 Gainers Connexa Sports Technologies Inc. (NASDAQ: CNXA) shares rose 73.5% to $0.1313 in pre-market trading after falling 15% on Monday. Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday September 19, 2023 Pre-market stock movers are a hot topic on Tuesday as investors seek out the latest news on the biggest traders this morning! Via InvestorPlace Billionaire Steve Cohen Invests $19M In Cybin For Psychedelics R&D, Blake Mycoskie's $100M Pledge Update September 18, 2023 Billionaire hedge fund and NY Mets owner, Steve Cohen amped up his support for psychedelics R&D through a new investment of nearly $19 million in beneficially owned shares of Cybin Inc. (NYSE: CYBN). Via Benzinga The 3 Most Undervalued Under-$1 Stocks to Buy in September 2023 September 14, 2023 Cheap valuations and prospects for future growth should get individual investors excited for these under-$1 stocks to buy. Via InvestorPlace NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years September 12, 2023 NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035. Via Benzinga Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More September 11, 2023 Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence Cybin's Intellectual Powerhouse Grows With New US Patent Covering Deuterated 5-MeO-DMT September 05, 2023 The U.S. Patent and Trademark Office (USPTO) has granted Canada-based psychedelics company Cybin Inc. (NYSE: CYBN) a new patent covering the composition of matter of deuterated 5-MeO-DMT analogs and... Via Benzinga Topics Intellectual Property Exposures Intellectual Property Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More September 05, 2023 Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 20 21 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.